JAN 20, 2022 7:30 AM PST

Researchers Stumble Upon Cancer Drug While Studying Flesh-Eating Bacteria

WRITTEN BY: Tara Fernandes

Scientists studying a neglected tropical disease have made a chance discovery—a promising therapeutic target for a deadly blood cancer. Institut Pasteur and Inserm researchers were investigating Buruli ulcers: infectious open sores caused by Mycobacterium ulcerans, a pathogen from the family of bacteria that cause leprosy and tuberculosis.

Buruli ulcers are a form of skin necrosis triggered by a toxin called mycolactone that the bacteria secrete. In previous studies, the scientists found that mycolactone affects the endoplasmic reticulum, a cell organelle that plays various roles, including producing hormones and lipids. The toxin blocks the function of the endoplasmic reticulum, ultimately resulting in the buildup of proteins inside the cell, causing it to self-destruct.

Interestingly, in their latest work, the researchers show that mycolactone is also incredibly lethal towards multiple myeloma cells, a cancer of mature plasma cells in the bone marrow. The researchers demonstrate that the toxin can kill tumor cells in animal models and tumor samples from patient biopsies. Most promisingly, mycolactone is harmless to healthy cells and is highly toxic to multiple myeloma cells that have become resistant to existing cancer therapies.

Factors such as radiation exposure and family history can contribute to an elevated risk of multiple myeloma, although the exact causes of the cancer are still unknown. The cancer is treated with steroids, stem cell transplants, or a class of chemotherapies known as proteasome inhibitors. While these therapies work well initially—particularly in patients at the early stages of the disease—over time, patients tend to become resistant to the treatment, and the cancer relapses.

The discovery of mycolactone’s powerful, selective effects on multiple myeloma cells paves the way for next-generation therapies with the potential to keep tumors in remission for longer, or possibly even permanently.

 

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
FEB 03, 2022
Immunology
Violet Extract Boosts Brain Cancer Drug's Performance
FEB 03, 2022
Violet Extract Boosts Brain Cancer Drug's Performance
Cyclotides are small, ring-shaped proteins produced by plants to defend themselves from certain insect pests and bacteri ...
JAN 30, 2022
Health & Medicine
What Happens After Omicron? Scientists' Predictions
JAN 30, 2022
What Happens After Omicron? Scientists' Predictions
Now that Omicron is running through the globe and increasing exposure to SARS-CoV-2 more than any previous variant, scie ...
FEB 08, 2022
Health & Medicine
Promising New Myasthenia Gravis Drug Completes Phase 3 Trial
FEB 08, 2022
Promising New Myasthenia Gravis Drug Completes Phase 3 Trial
Zilucoplan, a peptide inhibitor under investigation for the treatment of generalized myasthenia gravis in adults, was fo ...
MAR 07, 2022
Neuroscience
Drinking Milk Aggravates Multiple Sclerosis
MAR 07, 2022
Drinking Milk Aggravates Multiple Sclerosis
A protein found in cow’s milk can trigger inflammation in the surrounding areas of neurons in mice, and may have i ...
APR 28, 2022
Immunology
Lipid Supplement May Reduce Inflammation in MS
APR 28, 2022
Lipid Supplement May Reduce Inflammation in MS
Administration of an inflammation-mediating lipid has shown promise in reducing multiple sclerosis-related inflammation ...
MAY 08, 2022
Technology
Detecting Cytokine Storm Through Sweat
MAY 08, 2022
Detecting Cytokine Storm Through Sweat
A cytokine storm is a severe immune system reaction where the body is flooded with cells and molecules (called cytokines ...
Loading Comments...